Yang F.O.Hsu N.C.Moi S.-H.Lu Y.-C.Hsieh C.-M.KING-JEN CHANGChen D.-R.Tu C.-W.Wang H.-C.Hou M.-F.2022-08-122022-08-1220181743-7555https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031499468&doi=10.1111%2fajco.12771&partnerID=40&md5=c277ac71d0d992a5e84bf2fa2f4955afhttps://scholars.lib.ntu.edu.tw/handle/123456789/616605Aim: PEGylated liposomal doxorubicin (PLD) has comparable efficacy and differing toxicity from conventional anthracyclines used to treat advanced breast cancer. This study compared disease-free survival and toxicity between PLD-based and conventional anthracycline-based regimens as adjuvant treatments for early-stage breast cancer. Methods: We analyzed disease-free survival (DFS) rates, and adverse events in 102 women with early-stage (I−IIIa) breast cancer who received adjuvant PLD-based chemotherapy from 2002 to 2008. Each patient was matched for age, stage at diagnosis, HER-2 expression and hormone therapy use to a patient treated with an epirubicin-based regimen. Fisher's exact and Pearson's chi-square tests were used for categorical data analysis. Kaplan−Meier analysis and Cox regression models were used to analyze DFS. Results: DFS at 5 years was 81.3% for PLD-based regimen and 82.3% for epirubicin-based regimen. This difference was not significant (p = 0.939). Stage IIIa disease was associated with a shorter DFS in univariate analysis (p = 0.048). In multivariate analysis that controlled for adjuvant treatment, age at diagnosis, stage, HER-2 expression, type of surgery and hormone and radiation therapy, stage IIIa disease (P = 0.023) and lack of hormone therapy (P = 0.024) were each independently associated with shorter DFS. Adverse events were evaluated, and with the exception of hand-foot syndrome, more grade 3 and 4 toxicities occurred in patients who received epirubicin-based regimens than in those given PLD-based regimens. Conclusion: For patients with early-stage breast cancer who received PLD-based adjuvant chemotherapy, 5-year DFS was comparable and toxicity was acceptable, yet different from those of patients who received epirubicin-based regimens.[SDGs]SDG3journal article10.1111/ajco.12771290450142-s2.0-85031499468